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LP-211 is a new, selective agonist of serotonin (5-hydroxytryptamine, 5-HT) receptor
7 (5-HT7-R), which is part of a neuro-transmission system with a proposed role in
neural plasticity and in mood, cognitive and sleep regulation. Adolescent subchronic
LP-211 treatment produces some persisting changes in rats’ forebrain structural and
functional parameters. Here, using pharmacological MRI (phMRI), we investigated
the effect of acute administration with LP-211 (10mg/kg i.p.), or vehicle, to adult
rats previously exposed to the same drug (0.25mg/kg/day for 5 days), or vehicle,
during adolescence (44–48 post-natal days); histology and immuno-histochemistry were
performed ex vivo to evaluate neuro-anatomical and physiological long-term adaptation
to pharmacological pre-treatment. The phMRI signal reveals forebrain areas (i.e.,
hippocampus, orbital prefrontal cortex), activated in response to LP-211 challenge
independently of adolescent pre-treatment. In septum and nucleus accumbens, sensitized
activation was found in adolescent pre-treated rats but not in vehicle-exposed controls.
Immuno-histochemical analyses showed marked differences in septum as long-term
consequence of the adolescent pre-treatment: increased level of 5-HT7-R, increased
number of 5-HT7-R positive cells, and enhanced astrocyte activation. For nucleus
accumbens, immuno-histochemical analyses did not reveal any difference between
adolescent pre-treated rats and vehicle-exposed controls. In conclusion, subchronic LP-211
administration during adolescence is able to induce persistent physiological changes in the
septal 5-HT7-R expression and astrocyte response that can still be observed in adulthood.
Data shed new insights into roles of 5-HT7-R for normal and pathologic behavioral
regulations.
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INTRODUCTION
The serotonin (5-hydroxytryptamine, 5-HT) receptor 7 (5-
HT7-R), the most recently identified member in the family
of G-protein-coupled serotonin receptors, is characterized by
a widespread expression in the central nervous system, in the
peripheral nervous system and in the periphery (Ullmer et al.,
1995; Pierce et al., 1997; Nilsson et al., 1999; Neumaiera et al.,
2001; Meuser et al., 2002). The topography of 5-HT7-R dis-
tribution in the brain, studied by several authors through the
use of different techniques (Mullins et al., 1999; Neumaiera
et al., 2001; Shirayama et al., 2001; Bonaventure et al., 2004),
demonstrated predominant expression within the hypothalamus,
thalamus, hippocampus, cortex, amygdala, and striatum. In line
with this ample expression, 5-HT7-R has been linked to several
functional roles, such as thermoregulation, learning and mem-
ory, hippocampal signaling, circadian rhythm, and sleep (Duncan
et al., 1999; Hagan et al., 2000; Ehlen et al., 2001). The receptor is
also involved in cognitive and emotional processes, including anx-
iety and depression (Hedlund and Sutcliffe, 2004; Meneses, 2004;
Wesolowska et al., 2006; Mnie-Filali et al., 2011), and it has been
recently proposed for a role in neurogenesis, synaptogenesis and
dendritic-spine formation, especially during development (Kobe
et al., 2012; Rojas et al., 2014).
This complex spectrum of functions attracted a great inter-
est for the development of chemicals able to modulate the
activity of this receptor in a targeted fashion. In recent years,
different selective 5-HT7-R antagonist and agonist compounds
have been developed. Among the latter, LP-211 is a novel ago-
nist whose in-vitro pharmacological properties make it suitable
for possible psychoactive effects (Leopoldo et al., 2008, 2011;
Hedlund et al., 2010). Preclinical evidence in mice demon-
strates consistent acute/sub-chronic effects onto exploratory
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motivation, anxiety-related profiles, and spontaneous circa-
dian rhythm (Adriani et al., 2012; Romano et al., 2014).
Moreover, given the putative role of 5-HT7-R in neural plas-
ticity during development, we recently postulated that receptor
stimulation may result in neuro-plastic changes leading to a
persistent alteration on forebrain circuits. Such developmental
effects of LP-211, originated by adolescent subchronic expo-
sure, have been recently demonstrated in rats using either a
behavioral approach (Ruocco et al., 2014a,b) or several differ-
ent in-vivo magnetic resonance (MR) techniques (Canese et al.,
2014).
The pharmacological MRI (phMRI), an application of func-
tional MRI (fMRI), has started to represent a robust approach
for the direct observation of drug action within the central ner-
vous system (Gozzi et al., 2008; Kocsis et al., 2013), and—in the
last years—it has become increasingly popular due to its non-
invasiveness and relative low cost. The signal measured by either
fMRI or phMRI is determined by local changes in the ratio of oxy-
genated to deoxygenated hemoglobin, and it is known as Blood
Oxygenation Level Dependent (BOLD) signal. In response to
neuronal activity, the locally elevated oxygen consumption leads
to a feedback increase of blood flow, resulting in a rise of blood-
oxygenation levels. In phMRI, changes in the BOLD signal are
observed in response to a pharmacological stimulus. A previous
study (Canese et al., 2011) revealed different phMRI responses
to selective or non-selective blockade of serotonergic pathways,
suggesting that the use of selective compounds, and notewor-
thy agonists such as LP-211, could give a deeper insight into the
serotonin system.
In this work, we investigated the differential response to acute
LP-211 administration in rats, as a function of adolescent sub-
chronic exposure to the same drug. The use of phMRI allowed
us a deeper view into persistent, long-term changes triggered by
developmental 5-HT7-R stimulation, by investigating the carry-
over sensitization of acute, hemodynamic effects induced by
LP-211. Only those brain areas, displaying a differential drug-
evoked phMRI signal as a function of pre-treatment, were then
selected for ex vivo histological and immuno-histochemical anal-
yses, in order to evaluate underlying neuro-anatomical and
neuro-physiological changes.
MATERIALS AND METHODS
All experimental procedures were approved by the Institutional
Animal Survey Board on behalf of the Italian Ministry of Health
(formal license to G.L.). Procedures were in close agreement with
the European Communities Council Directive (86/609/EEC) and
Italian law. All efforts were made to minimize animal suffering, to
reduce the number of animals used, and to utilize alternatives to
in-vivo techniques, if available.
SUBJECTS
Twenty male Wistar rats from our colony were housed in pairs
inside polycarbonate cages (42.5 × 26.6 × 18.5 cm) with sawdust
bedding, in an air-conditioned room (21 ± 1◦C, relative humid-
ity 60 ± 10%), on a 12-h reversed light-dark cycle (lights off at
7.00 a.m.). Food (Altromin-R, A. Rieper S.p.A., Vandoies, Italy)
and tap water were provided ad libitum.
PHARMACOLOGICAL TREATMENT
Rats were randomly assigned to receive a sub-chronic intraperi-
toneal (i.p.) administration of LP-211 (LP, 0.250mg/kg/day, n =
10), or vehicle (VEH, 1%DMSO in saline, n = 10) for 5 days dur-
ing the adolescent phase (43–47 post natal days, PND). The drug
dosage was chosen according to previous data obtained in mice
and rats (Adriani et al., 2012; Canese et al., 2014; Romano et al.,
2014; Ruocco et al., 2014a,b).
At adulthood (63–75 PND; weight range: 340–430 g), rats
underwent phMRI, with an acute challenge of either LP-211
(10mg/kg i.p.), or vehicle. Our aimwas tomeasure acute response
to LP-211 challenge, modulated by the different pre-treatments.
Animals were therefore subdivided into three final experimental
groups, according to the substance administrated in the ado-
lescent phase (subchronic pre-treatment) and during phMRI
analyses (acute administration): 1. the adolescent subchronic
VEH + acute VEH (VEH+VEH) and the adolescent subchronic
LP-211 + acute VEH (LP+VEH) were collapsed, generating
a single “vehicle-challenge” group (VEH), since no differences
between these two groups were observed in preliminary phMRI
data analyses; 2. adolescent subchronic VEH + acute LP-211
(VEH+LP: acute challenge in drug-naive rats); 3. adolescent sub-
chronic LP-211 + acute LP-211 (LP+LP: sensitized response to
the challenge).
PREPARATION OF ANIMALS FOR phMRI
Anesthesia was induced with isoflurane (Esteve veterinaria, Spain,
5% for induction and 2.5% during the set-up) in O2 and then
rats were intubated and mechanically ventilated [90 bpm, volume
depends on animal weight following the formula: strokes vol-
ume (ml) = animal weight (g) × 0.0062]. Artificial ventilation
allows triggering all functional acquisitions at the same instant
of breath cycle, thus minimizing motion artifacts and preventing
drug-induced alterations in the respiratory rate when the LP-211
challenge is injected.
Rats were fixed on the cradle using a stereotaxic head frame
to reduce head movements. A cannula was inserted subcuta-
neously to administrate a bolus of medetomidine (Domitor,
Pfizer Germany, 0.05mg/kg in 0.5ml) and then connected to
the infusion line for continuous medetomidine administration
(0.1mg/kg/h in 1ml/h). The continuous infusion of the anes-
thetic started 15min after bolus; at the same time, isoflurane
was reduced to 0.6%. A second cannula was inserted into the
peritoneum and connected to an infusion line for remote drug
administration during the MRI session. An integrated heating
system allowed maintaining the animal body temperature at
37.0 ± 0.1◦C.
Rats were monitored during MR scanning using a MRI-
compatible pulse oximeter (MouseOx, Starr Life Sciences Corp)
that provides on-line measures of heart rate, oxygen saturation,
and pulse distension (a surrogate parameter for blood pressure;
its measured values depend on the intensity of the pulse-oximeter
signal, therefore we normalized its actual value to a percentage
of maximum in the time course of each animal). After the scan,
medetomidine was antagonized using the antidote, atipamezole
(Antisedan, Pfizer Germany, double dose with respect to medeto-
midine in 0.5ml s.c.) that ensures a fast awakening and recovery
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of all animals. A wash out period of at least 1 month was left
before sacrifice.
phMRI PROTOCOL AND ACQUISITION
Experiments were performed on a VARIAN/Agilent Inova
MRI/MRS system operating at 4.7 T equipped with an actively
shielded gradient system (max 120mT/m, 11 cm bore size). A vol-
ume coil of 6-cm diameter was used for transmission in combi-
nation with an electronically decupled receiver-only surface coil
(Rapid Biomedical, Rimpar, Germany). The shape of this receiver
coil (3 cm long, 3 cm wide, and 1 cm high) was designed to opti-
mally fit the dorsal surface of the rats’ heads centered over the
forebrain regions.
Gradient echo scout images were used to detect position
of each animal’s head inside the magnet. Then, fast spin-echo
sagittal anatomical images (TR/TEeff = 3000/15ms, 15 consec-
utive slices of 1mm thickness, FOV = 40 × 40mm2, matrix of
256 × 256, 4 averages, voxel resolution = 0.31 × 0.31 × 1mm)
were used to accurately position axial images for the pharma-
cological study. In order to have a reproducible positioning of
acquired slices, we considered the forceps minor of the cor-
pus callosum as reference (Canese et al., 2009) as shown in
Figure 1.
Echo planar breath-triggered images were acquired (TR ≈
4000ms, TE = 23ms, matrix 64 × 64, FOV 25 × 25mm2, slices:
6, thickness 1mm, 1 average). After consecutive image collec-
tion for about 12min (20 baseline images), rats received LP-211
(10mg/kg i.p.) or vehicle (1ml/200 g body weight). Images were
then collected for further 24min (40 post-challenge images).
phMRI DATA AND STATISTICAL ANALYSES
Data were analyzed by a home-made program (developed in
Matlab, Mathworks Inc.) as previously described (Canese et al.,
2009, 2011). During the pre-processing, images were realigned
in order to reduce the artifacts due to animal movements dur-
ing data acquisition (Canese et al., 2009). Once the images
were realigned, they were then restored in order to increase the
signal-to-noise ratio (SNR). In order to efficiently smooth the
rough data, we implemented a procedure based on a moving
average data interpolation. Then, two-step statistical approaches
were conducted in parallel (Canese et al., 2011) on the acquired
datasets.
First step
We constructed a template for each group: after selecting the
dataset of one subject as a reference for the group, the datasets
of the other subjects were transformed by means of a poly-nomial
transformation (Goshtasby, 1988). Once the image sequences had
been co-registered to the reference images, the software aver-
aged the whole data acquired from all individual datasets of each
group in order to obtain one template per group. Within each
template, significant temporal alterations in BOLD signal pro-
files were assessed pixel-by-pixel, through a random effect analysis
comparing a post challenge time window (five-point wide win-
dow centered on the signal maximum) to the mean baseline
signal, with a two tailed Student t-test (p < 0.065, Bonferroni
corrected).
Second step
We extracted BOLD signal intensity timecourses, i.e., one curve
for each individual animal, from several brain areas. These
regions-of-interests (ROIs) were selected (manually, on the tem-
plate images, Figure 2) based on those areas showing apparent
activation in LP+LP but not VEH+LP templates. We therefore
selected: hippocampus (Hip) in slice 2; septum, dorsal striatum
(Str) and frontal cortex in slice 4; medial prefrontal cortex, dorso-
lateral prefrontal cortex and nucleus accumbens (NAcc) in slice 6,
according to the activation maps of group templates.
FIGURE 1 | Positioning of the six slices for phMRI, overlaid on the
anatomical sagittal fast spin-echo images taken from an individual
representative rat. We acquired six slices in total: three consecutive
slices (thickness 1mm), centered on the hippocampus (Hip, slice 1, 2,
3), as well, after a gap of 3mm, other three slices. These were
centered, respectively, on: dorsal striatum (dStr, slice 4), on the fibers
between the prefrontal cortex and striata (slice 5), on prefrontal cortex
(PFC, slice 6).
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FIGURE 2 | Right panels: localization of ROIs. Left panels: BOLD
activation maps (the Student-t-values, in color scale), overlaid on
anatomical images (in gray scale). Both are taken from the three brain
templates, originating from rats receiving: vehicle challenge (VEH), LP-211
acutely only (in drug-naive subjects) i.e., following adolescent vehicle
exposure (VEH+LP), LP-211 also in acute but following adolescent
subchronic pre-treatment (LP+LP). Only pixels with significant values
(p < 0.065 for slice on Hip and p < 0.05 for the others) are illustrated.
ROIs were taken with the help of the Atlas (Paxinos and Watson, 1998)
from: the CA1-CA2 fields of Hip (red regions at −3.30 from bregma, slice
2); from the dSTR, septum and frontal cortex (see green, blue, red ROIs,
respectively, at +0.7 from bregma, slice 4); from the nucleus accumbens,
medial prefrontal cortex, dorsal prefrontal cortex (see green, blue, red,
ROIs, respectively, at +2.7 from bregma, slice 6).
In the timecourses for the extracted BOLD signal curves, each
temporal point was obtained by averaging the BOLD signal inten-
sity values across all chosen-ROI pixels at that time point. In such
BOLD timecourses, each time point was expressed as the percent-
age change of the signal intensity from the first time point. These
BOLD timecourses underwent normalization of baseline and de-
trending. In particular, the baseline mean values (estimated as an
average of the first 20 time points) were subtracted from each
BOLD timecourse. This, in order to decrease inter-individual
variability due to random (instrumental and biological) fluctua-
tions in the first timepoint. Then, for each individual rat, a linear
regression fit was applied to the first 20 and last 15 time points,
in order to estimate the temporal drift of the curve. This drift line
was then subtracted from the entire BOLD timecourse (Canese
et al., 2009, 2011).
Like for group templates, animals receiving acute vehicle chal-
lenge (LP+VEH andVEH+VEH)wheremerged in a single group
(VEH): this, since preliminary analyses yielded no differences
between these two groups, as expected. Split-plot ANOVA was
thus performed, with group (three levels: LP+LP vs VEH+LP
vs VEH) as between subjects factor, time (40 points after injec-
tion, 24min) and side (right vs left hemispheres except for
septum and medial prefrontal cortex) as within subject factors.
Analyses were performed on the post-challenge curves, in search
for drug-induced effects. Tukey’s Honestly Significant Difference
(HSD) test was used for multiple post-hoc comparisons (Abdi and
Williams, 2010).
TISSUE SAMPLING AND PROCESSING
At sacrifice, brain hemispheres were fixed in 4% buffered
formaldehyde and blind coded brain slices were obtained from
four standard coronal sections (2-mm thick). The slices were
washed in running water, dehydrated in graded alcohols, cleared
in xylene and finally embedded in paraffin wax. 5-µm-thick sec-
tions were cut on microtome, and collected onto glass slides for
histological and immuno-histochemical analyses.
Histology and immuno-histochemistry
For histological analyses, the slides were deparaffinized, rehy-
drated, and stained with haematoxylin/eosin or with luxol fast
blue/eosin for the precise identification of the brain structures.
For immuno-histochemistry, sections were collected on Super
Frost Plus slides and immunostained according to the ABC
method for brightfield examination.
Briefly, sections were deparaffinized, rehydrated and subjected
to antigen retrieval by microwaving in citrate buffer. The slides
Frontiers in Behavioral Neuroscience www.frontiersin.org December 2014 | Volume 8 | Article 427 | 4
Altabella et al. Adolescent exposure to 5-HT7 agonism
were then treated with 3% hydrogen peroxide in methanol to
block endogenous peroxidases activity, rinsed in PBS, blocked
for 1 h in PBS containing 3% normal goat serum and then
incubated overnight at 4◦C with one of the following anti-
bodies: 5-HT7-R (cod. NBP1-46598, Novus Biologicals, rabbit,
1:1000 dilution); post synaptic marker PSD95 (cod. NBP1-47642,
Novus Biologicals, mouse, 1:500 dilution); neuro-filament NF-L
(DA2) (cod. NB 300-132, Novus Biologicals, mouse, 1:250 dilu-
tion); GFAP for astrocytes (cod. M0761, DAKO, mouse, 1:100
dilution).
Subsequent antibody detection involved incubation with the
appropriate biotinylated secondary antibody for 1 h (1:200 dilu-
tion, Vector Laboratories, Italy) at room temperature, fol-
lowed by incubation with the avidin-biotin-peroxidase complex
(Vectastain ABC-Elite kit, Vector Laboratories, Italy) according to
the manufacturer’s instructions. The samples were stained with
3′-3′diaminobenzidine (DAB, Sigma, Italy) as chromogen to visu-
alize the reaction product and then lightly counterstained with
haematoxylin.
For immuno-fluorescence, sections were processed as above
but the antibody detection was performed through 1 h of incu-
bation with Alexa Fluor 488 secondary antibody (1:300 dilution,
Invitrogen, Italy). In order to obtain comparable data and a more
consistent staining, each antibody was tested on both groups in
the same immuno-histochemical run.
For the count of 5-HT7-R and GFAP positive cells and for
densitometric measures, anatomical landmarks were used as opti-
cal reference so that equal areas at the rostrocaudal levels were
analyzed for each animal. Three non-consecutive serial sections
from each brain were photographed under 20× magnification,
with constant light conditions, and the labeled cells were counted
manually in selected brain areas (i.e., nucleus accumbens and sep-
tum). Staining intensities were quantified on immunofluorescent
slides using ImageJ software (NIH, http://rsb.info.nih.gov/ij). 5-
HT7-R intensities were calculated using the mean intensity value
of the 5-HT7-R positive cells. For that, RGB images were splitted,
the green channel was selected and 8-bit converted. Images were
then thresholded and ROIs selected for quantification. Optical
densities of the ROIs were recorded and expressed as values on
a gray scale, ranging from 0 (black) to 255 (white). For statistical
analysis, student t-test was used.
RESULTS
Heart rate and pulse distension, measured pre and post chal-
lenge during the phMRI study, are summarized inTable 1. Typical
Table 1 | Physiological parameters in rats during Ph-MRI
measurements, before (Pre) or after (Post) the challenge
administration.
Heart rate (bpm) Pulse distension (%)
Experimental Pre Post Pre Post
group
(VEH or LP)+LP 234.36 ± 36.20 218.20 ± 32.61 89 ± 4% 73 ± 9%
VEH 226.70 ± 23.53 219.74 ± 20.58 84 ± 2% 66 ± 10%
time courses are shown in Supplementary Figure 1. No statistical
differences were found in the data between the LP-211 chal-
lenge and vehicle controls [ANOVA with repeated measurements,
F(1, 8) = 2.71, n.s., F(1, 8) = 0.03, n.s., respectively], confirming
that LP-211 challenge did not alter the depth of anesthesia in rats.
Oxygen saturation is not relevant in these experiments because
animals weremechanically ventilated with oxygen at 99% (instead
of air) during MR measurements. Therefore, this parameter was
constant during the whole experiment.
A significant reduction in pulse distension between pre and
post challenge is present in all groups [time, F(1, 8) = 41.45,
p < 0.001]. This reduction cannot be attributed to LP-211
challenge or pre-treatment since it is present also in vehicle con-
trols, and it is probably due to the prolonged anesthesia or to
cardiovascular readjustment to the volume of injection. Finally,
time courses of physiological parameters measured during MR
scan pre and post challenge were compared to time courses of
BOLD curves and we found they were temporally uncoupled.
Our findings are not in conflict with the increased wakefullness
in rats due to LP-211, as reported in literature (Romano et al.,
2014). In fact, in our case, rats were anesthetized with a double
anesthetic (isoflurane and medetomidine) that likely overcomes
the behavioral effect of LP-211 already reported.
TEMPLATES’ ACTIVATION MAPS, BOLD TIMECOURSES
No consistent activation was found in the VEH template. As for
drug challenged groups, activation maps showed BOLD signal
hyper-intensity within several regions, with different extension
and intensity depending on the adolescent, subchronic pre-
treatment. Areas of a positive BOLD effect (i.e., regions whose
pixels exceeded the threshold of significance) were detected,
within the LP+LP but not the VEH+LP group, for the hippocam-
pus (CA1-CA2 fields, slice 2), septum, frontal cortex, and part of
dorsal striatum (slice 4), as well as for medial prefrontal cortex,
dorso-lateral prefrontal cortex and the nucleus accumbens (slice
6). The orbital prefrontal cortex was the only region showing
clear-cut activation in templates for both VEH+LP and LP+LP
groups.
Therefore, as shown in Figure 2, the VEH+LP group showed
a differential response to the challenge with respect to the LP+LP
group. In particular, for drug-naive animals receiving LP-211 for
the first time as an acute challenge (i.e., VEH+LP template),
non-localized and/or widespread effects were observed, with just
scattered pixels or reduced extension of activation, in hippocam-
pus and at the level of the nucleus accumbens. In this template,
the septum, frontal cortex and dorsal striatum, as well as dorso-
lateral and medial prefrontal cortex, did not show any significant
response; therefore, for the latter areas, the VEH+LP and VEH
templates were undistinguishable, suggesting no effect at all of an
acute LP-211 challenge in drug-naive rats.
Localization of the seven regions, for time-courses extraction
and analysis, is shown in Figure 2 right panel. Analyses of the
BOLD timecourses, individually extracted from subjects, con-
firmed a differential activation for just three out of the seven
chosen areas (see Figure 3): for hippocampus, nucleus accum-
bens, and septum. Data showed that the BOLD effects differed
between LP+LP and VEH+LP experimental groups. Significant
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FIGURE 3 | Mean ± s.e.m. change (%) in BOLD signal timecourses, in the
CA1-CA2 fields of Hip, septum and nucleus accumbens (ROIs shown in
Figure 2), for rats receiving vehicle challenge (VEH), LP-211 acutely only
(in drug-naive subjects) i.e., following adolescent vehicle exposure
(VEH+LP), LP-211 also in acute but following adolescent subchronic
pre-treatment (LP+LP). Time after the challenge is expressed over ten
3-min intervals, obtained by averaging the originally acquired data in ten
5-point-wide time-windows. Significant post-hoc Tukey comparison (LP+LP
vs VEH+LP groups) are indicated as follows:
(∗)0.05 < p < 0.1;∗ p < 0.05;∗ p < 0.01.
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interactions time × treatment were indeed found only in septum
[F(80, 360) = 1.43, p = 0.015], in hippocampus [F(80, 360) = 1.70,
p = 0.006], and in nucleus accumbens [F(80, 280) = 1.55, p =
0.005]. For both septum and nucleus accumbens, the post-hocs
confirmed that a BOLD effect was evident in LP+LP and absent
in VEH+LP curves. For the hippocampus, an activation signal
was present in both the LP+LP and VEH+LP groups (though
with different intensities and temporal outline, see Figure 3).
This, together with the scattered points already mentioned by
VEH+LP template inspection, suggested that this area was indeed
activated in drug-naive rats, after a single acute LP-211 adminis-
tration.
For medial and dorso-lateral prefrontal cortex, frontal cortex,
as well as dorsal striatum (all of which appeared to be activated
on LP+LP template but clearly devoid of activated pixels on
VEH+LP template), ANOVAs did not confirm the profile (data
not shown): as such, the pixels activated on template may well be
a false positive. The ANOVA on timecourses was not necessary for
orbital prefrontal cortex, as this area was clearly activated in both
LP+LP and VEH+LP groups.
EX VIVO HISTOLOGY AND IMMUNO-HISTOCHEMISTRY
We performed histological examinations of luxol fast blue and
haematoxylin-eosin stained slides obtained throughout the whole
brain. This morphological analysis showed no relevant alter-
ation in LP+VEH vs VEH+VEH animals. In-depth immuno-
histochemical analyses, for the evaluation of neuro-anatomical
and neuro-physiological changes, were then conducted in two
selected brain areas. We chose the nucleus accumbens and the
septum, the only two regions with positive phMRI activations for
the LP+LP group only, confirmed both in template maps and
in BOLD timecourse analyses (depicted in Figures 2, 3). These
areas could possibly have developed stable neuro-anatomical or
neuro-physiological changes, induced by subchronic treatment
with LP-211 during adolescence.
The ex vivo investigation for prefrontal and frontal cortex
regions as well as dorsal striatum was not performed, because
these areas resulted not to significantly differ, as a function of
pre-treatment, in the ANOVA analyses. Conversely, for the orbital
prefrontal cortex and the hippocampus, activation signal was
present, after acute LP-211 administration, in both the LP+LP
FIGURE 4 | Analysis of 5-HT7-R and GFAP immunoreactivity in the
nucleus accumbens (NAcc) and in the septum: statistically significant
differences were observed only in the septum. Here, animals
subchronically pre-treated during adolescence with LP-211 drug showed an
increased 5HT7-R optical density and an increased number of GFAP-positive
cells with respect to VEH-exposed control group (C). The values are given as
mean ± SE; asterisks denote a statistically significant difference (p < 0.05).
No differences for 5HT7-R were observed by cell count in both areas.
(A,B) are representative photomicrographs at the level of the NAcc and
septum in Luxol fast blue-stained slides.
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and VEH+LP groups; therefore, an ex vivo analysis in these two
regions was out of the purposes of present study.
Regarding the 5-HT7-R expression, counting of immunoreac-
tive cells in the septum revealed no differences in the total number
of 5-HT7-R expressing cells between the two groups. Conversely,
the analysis of the 5-HT7-R optical density revealed a signif-
icant increase in immunoreactivity for the group subjected to
adolescent pre-treatment, compared to adolescent VEH-exposed
controls (Figure 4). These results indicate increased levels of
receptors expressed by septal cells, as a long-term consequence
of adolescent LP-211 treatment. Besides the 5-HT7-R changes,
we found an increase in GFAP immunoreactivity (Figure 5),
suggesting persistent rearrangement with an increased response
of astroglial cells in adolescent-LP-211 pre-treated animals. No
differences were observed with the post-synaptic and with the
neuro-filament markers.
In the nucleus accumbens, neither the cell counts nor optical
density analyses of 5-HT7-R positive cells revealed any difference
between adolescent drug pre-treated animals and VEH-exposed
controls (see Figure 4); likewise, no differences were observed
with the other markers. Such results suggest that the subchronic
pre-treatment with LP-211 during adolescence does not produce
an immuno-histochemically detectable effect on this brain area,
at least regarding the selected markers.
DISCUSSION
The present work was aimed to study the long-term sensitizing
effects of the adolescent, subchronic administration of LP-211,
a novel 5-HT7-R agonist. To do this, a two-level approach was
adopted: first, adult rats underwent phMRI analyses (with an
LP-211 challenge) following a previous adolescent exposure, to
identify LP-211 sensitized areas which were not acutely responsive
in drug-naive rats; once identified, these (two) areas were studied
ex vivo, at the histological and immuno-histochemical level, to
detect the presence of stable neuro-anatomical and biochemical
changes.
General anesthesia is usually induced in rodents during phMRI
studies in order to reduce motion artifacts, to minimize the stress
produced by prolonged restraint and MRI gradient noise, and
to facilitate animal handling (Lukasik and Gillies, 2003; Sicard
et al., 2003; Steward et al., 2005). Unfortunately, general anesthe-
sia may perturb cerebral blood flow and metabolism, as well as
electro-physiological, cardio respiratory, and other physiological
parameters; finally, it can suppress neuronal activity reducing the
BOLD response (Gozzi et al., 2008). Recent studies reveal that
BOLD response to the same challenge may change from nega-
tive to positive, or differ in amplitude, with different anesthetic
regimes (Sommers et al., 2009; Hodkinson et al., 2012; Liu et al.,
2012). Also, the pharmacological challenge in itself can produce
cardio respiratory physiological responses that may alter hemo-
dynamic measurements in brain. The particular sensitivity of
phMRI to natural and anesthesia-induced fluctuations in vital
parameters is a well-documented issue, affecting the quality and
interpretation of phMRI results. For such reasons, in the last years
several studies have tried experimental procedures to achieve
the most reliable and reproducible phMRI acquisition protocol
(Steward et al., 2005; Weber et al., 2006; Ferrari et al., 2012).
For these reasons, the present work exploited a protocol for
sedation and anesthesia consisting of two anesthetic compounds
(isoflurane and medetomidine), under continuous supply, asso-
ciated with intubation, and mechanical ventilation, to assure
stability in physiological parameters: such a protocol is suitable
for prolonged investigations (Weber et al., 2006; Fukuda et al.,
2013). This protocol also assures a fast recovery of the animals and
therefore it is suitable for longitudinal studies as well as for fur-
ther behavioral testing (Canese et al., 2014). Once optimized, this
setting (anesthetic regimen combined to the respiratory trigger)
allowed to acquire phMRI scans of the desired resolution, with
signal alterations as low as 0.5% and strongly reduced motion
artifacts.
Moreover, physiological parameters (heart rate and pulse dis-
tention) measured during MR scan, pre and post challenge,
did not show differences due to LP-211 administration. We can
exclude any bias due to cardiovascular rearrangements or sys-
temic alterations, and therefore attributed to LP-211 any effect
observed in BOLD signal variations.
In this way, we found robust and significant results by using
and comparing data obtained with two different and paral-
lel statistical approaches (Canese et al., 2011). By using this
combined approach, we were able to identify significant alter-
ations in several forebrain areas. The orbital prefrontal cortex
and hippocampus were the only regions showing a clear-cut
activation due to drug challenge, with no differences between
adolescent-LP-211 pre-treated (LP+LP) and adolescent-VEH
exposed (VEH+LP) groups; therefore, these were not further
investigated ex vivo. Conversely, in the absence of acute response
to LP-211 (10mg/kg i.p.) within drug-naive subjects, two areas
showed a sensitized response to the same drug due to previ-
ous developmental exposure. Indeed, in the septum as well as in
the nucleus accumbens, BOLD response was evident within the
LP+LP group but not in the VEH+LP one. A somewhat simi-
lar profile seemed to emerge for frontal and prefrontal cortex as
well as (part of) dorsal striatum, at least in template activation
maps, but this was not confirmed by ANOVA analyses on BOLD
timecourses.
The suggestion of a persistent modification in neurocir-
cuitry, supported by recent data (Canese et al., 2014), was
further examined with immuno-histochemistry. In the absence
of detectable changes for the nucleus accumbens, the septum
revealed the most interesting differences between adolescent-LP-
211 pre-treated vs. adolescent-VEH exposed rats after ex vivo
immuno-histochemical examination. In particular, sub-chronic
administration of LP-211 during adolescent phase exerted a direct
and long-lasting effect in the septal area, with a specific increase of
5-HT7-R immunoreactivity coupled with an increased astrocytes
response (as observed by GFAP immunoreactivity).
These two aspects may well be related. The observed increase
in astrocytes response within the septum could represent a spe-
cific, yet secondary response to an increased 5-HT7-R immunore-
activity in local neurons, produced by the LP-211 adolescent
pre-treatment. Together with this, it is possible that the increased
5-HT7-R immunoreactivity, observed in the septum, derives, at
least in part, from an increased receptor expression in activated
astrocytes. Consistently, 5-HT7 receptors have been classically
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FIGURE 5 | Analysis of GFAP immunoreactivity in the nucleus accumbens
(NAcc) and in the septum: significant differences were observed only in
the septum. Here, animals subcronically pre-treated during adolescence with
LP-211 drug (A) revealed an increased GFAP immunoreactivity, with respect
to the VEH-exposed control group (B). No differences were conversely
observed in the nucleus accumbens (C,D). Original magnifications 40×.
reported in glial processes within the supra-chiasmatic nucleus
(Glass and Chen, 1999; Belenky and Pickard, 2001), in astrocytes
from the frontal cortex (Shimizu et al., 1996), and in primary
astrocyte cultures (Hirst et al., 1997).
The idea of astrocytes as primary players in the pathophys-
iology of the CNS is not new: astrocytes are key elements
that participate in all essential CNS functions. They represent
a wide and heterogeneous population of cells whose activity is
finely regulated on the basis of specific functions and responses
of their relevant neuronal population (Fellin, 2009). In recent
years, astrocytes are emerging as relevant and active elements in
brain physiology, where they act by exchanging information with
the synaptic neuronal elements, responding to synaptic activ-
ity and regulating synaptic transmission. The term “tripartite
synapse” is now used to represent the bi-directional communi-
cation between astrocytes and neurons at the synapse’s interface
(Araque et al., 1999). In line with this, a major role of astrocytes
is the uptake of neuro-transmitters, mainly glutamate and GABA,
therefore contributing to modulate local network transmission.
Variations in neuro-transmitter levels (mainly glutamate) were
already observed, after adolescent subchronic LP-211 adminis-
tration, in previous work by our group: through amino-acid
detection ex vivo, within prefrontal and striatal areas (Ruocco
et al., 2014a,b) and through MR spectroscopy, within the hip-
pocampus (Canese et al., 2014). We could speculate that similar
variations might also occur in the septum, and this would rep-
resent a further stimulus for an increased astrocytes immunore-
activity. We did not observe any variation in neuro-filament and
synaptic markers, supporting the conclusion of a predominantly
glial modification.
Surprisingly, we have not found immuno-histochemical vari-
ations in the nucelus accumbens, the other area where sensitized
BOLD responses to LP-211 were observed with our phMRI anal-
yses. Although undetectable in our hands, we cannot exclude
that adolescent LP-211 administration resulted in variations of
the same markers, which were below the detectable level with
immuno-histochemistry but would become evident if tested with
other techniques. In any case, a set of morphological and func-
tional changes (in the dendritic tree and network connections)
were already revealed for the nucleus accumbens in our previ-
ous work (Canese et al., 2014). It is therefore possible that, in
the absence of changes on the selected markers, persistent modi-
fications could subtend the activation of other proteins or effec-
tor patterns downstream of the 5-HT7-R activation, and/or the
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mirroring of drug-evoked effects originated from other areas then
projecting into the nucleus accumbens, as opposed to the direct
effect clearly observed in the septum. Accordingly, we found in
our previous work (Canese et al., 2014) that long-term functional
modifications, produced by adolescent LP-211, were tapping onto
the limbic loop in general and nucleus accumbens in particular.
If so, the altered phMRI signal could be interpreted as an indi-
rect effect (of the adolescent LP-211 administration), primarily
evoked in another node of the loop (e.g., the hippocampus or
orbital prefrontal cortex, actually stimulated). Conversely, while
the septum was persistently modified in its anatomy (present
data), it did not emerge as part of the functional connectivity
alterations induced by adolescent LP-211 in our previous data
(Canese et al., 2014).
As a final remark about drug dosage, LP-211 (10mg/kg) has
been used in various in vivo studies (Hedlund et al., 2010;
Martinez-Garcia et al., 2014; Meneses et al., 2014), and effects
possibly mediated by the activation of 5-HT1A or 5-HT2B recep-
tors were not observed (i.e., body temperature, cardiac failure,
respectively). Therefore, although the dosage is relatively high,
we can confidently assume that LP-211 is still selective to 5-HT7
receptor.
CONCLUSION
In summary, our results suggests that subchronic LP-211 admin-
istration during the adolescent phase is able to induce physi-
ological changes in the 5-HT7-R expression and in astrocytes
response, within the septum, that can still be observed in adult-
hood. The increased number of GFAP-positive cells within the
septum, found in the present work, is not yet related to the evi-
dence of a rearranged connectivity, recently found within the
whole limbic loop (Canese et al., 2014). Therefore, further stud-
ies are required to better clarify the nature and the output of such
enduring changes.
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